Immunology company argenx SE (Euronext Brussels:ARGX) (Nasdaq:ARGX) and biopharmaceutical company Zai Lab Limited (Nasdaq:ZLAB) (HKEX:9688) revealed on Tuesday that they have received Chinese regulatory approval for efgartigimod alfa injection (subcutaneous injection) (efgartigimod SC) 1,000mg (5.6ml)/vial for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.
The approval is based on positive results from the Phase 3 ADAPT-SC study, which demonstrated similar efficacy and safety compared to the intravenous formulation.
Efgartigimod SC is also being evaluated for chronic inflammatory demyelinating polyneuropathy (CIDP) in China and has been approved for CIDP in the United States.
LEO Pharma reports positive phase 2b results for temtokibart in atopic dermatitis
New England Biolabs achieves B Corporation recertification
Palatin presents symptom resolution data from Phase 3 dry eye disease trial
BioArctic expands exidavnemab trial to include Multiple System Atrophy patients
NeuroSense Therapeutics completes PrimeC commercial manufacturing scale-up
SCG releases SCG101 late-breaking clinical data in HBV-related hepatocellular carcinoma
Genprex signs new research agreement with University of Pittsburgh to advance diabetes gene therapy
AstraZeneca and Daiichi Sankyo's Enhertu shows strong results in early-stage breast cancer trial